Universal reference book for medicines

Active substance: measles, mumps and rubella virus vaccine live

Type: Vaccine for the prevention of measles, mumps and rubella

Manufacturer: SERUM INSTITUTE OF INDIA (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

It causes the formation of immunity against the virus of measles, mumps and rubella.
After a single injection of the vaccine, the body produces the appropriate antibodies. Children under the age of 15 months may not have a response to the measles component of the vaccine due to the presence of circulating residual measles antibodies obtained from the mother. The smaller the age of the child, the less likely the seroconversion.
After vaccination, the level of antibodies in the blood persists for more than 11 years.

Conducting routine immunization of children against measles, mumps and rubella;
carrying out revaccination of children against measles, mumps and rubella;immunization of persons planning to travel abroad, who lack immunity to measles, mumps and rubella; immunization of women of childbearing age who do not have immunity against rubella; immunization of women susceptible to rubella in the postpartum period; immunization of non-rubella immunized children whose mothers are susceptible to rubella.
The vaccine is injected into the area of ​​the outer surface of the shoulder.
The dose is the same for all patients. The frequency of administration is determined in accordance with the vaccination and revaccination schemes.
Possible: rapid burning or soreness at the injection site;
fever, rash, mumps, nausea, vomiting, diarrhea, thrombocytopenia, purpura, regional lymphadenopathy, skin reaction with flushing and blisters at the injection site, erythema, skin tightening and sensitivity, erythema multiforme; anaphylactic and anaphylactoid reactions, urticaria, myalgia, arthralgia and / or arthritis, polyneuritis, seizures, headache, dizziness, paresthesia, polyneuritis, Guillain-Barre syndrome, ataxia, optic neuritis, ocular nerves, otitis media, deafness associated with defeat of nerves, conjunctivitis; orchitis.
Anaphylactic, anaphylactoid and other immediate-type hypersensitivity reactions to egg whites, neomycin;
diseases of the respiratory system; infectious disease accompanied by fever; untreated tuberculosis in the active phase; conducting immunosuppressive therapy; malignant diseases of the blood and lymphatic system;primary and acquired immunodeficiency (including AIDS or other clinical manifestations of HIV infection); disorders of cellular immunity; hypogammaglobulinemia or disgammaglobulinemia; the presence of congenital or hereditary immunodeficiency in a family history before determining the state of the patient's immune system;pregnancy.
The study of the effect of the vaccine on reproductive function, as well as on the fetus in case of vaccination in pregnancy, was not conducted.

With caution apply the vaccine to a nursing mother during lactation.

Women of childbearing age should use reliable contraceptives within 3 months after vaccination.

In children and young adults infected with HIV, but without obvious clinical manifestations of immunosuppression, vaccination is allowed, but it may be less effective than in uninfected individuals.

The vaccine is not given IV.

Given the possibility of developing anaphylactic and anaphylactoid reactions, the vaccine should be administered under conditions that allow for emergency therapy.

With special care apply in patients with a history of convulsions (including family history), damage to brain tissue and any other conditions in which it is necessary to avoid a rise in body temperature.

According to some data, if the reactions associated with the consumption of chicken eggs were not anaphylactic or anaphylactoid, the likelihood of complications in the introduction of the vaccine is not increased.

In children and young adults infected with HIV, but without obvious clinical manifestations of immunosuppression, vaccination is allowed, but it may be less effective than in uninfected individuals.
Vaccinated should avoid contact with patients with measles, mumps and rubella. To assess the state of immunity and to provide adequate protective measures with a marked decrease, when necessary, levels of circulating antibodies can be determined.
Vaccination should not be performed for at least 3 months after a blood or plasma transfusion, the administration of human immunoglobulin.

In most patients, within 7-28 days after vaccination, small amounts of live attenuated rubella virus from the nose and pharynx were noted.
The possibility of transmission of the virus in this way from vaccinated to other people has not been proven.
There are reports that live attenuated vaccines against measles, mumps and rubella in some cases cause a temporary depression of skin sensitivity to tuberculin.Therefore, if necessary, tuberculin samples should be taken before or simultaneously with the administration of this vaccine.

This vaccine, like any other, does not cause 100% seroconversion in people susceptible to viral infections.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!